LABEST 2021 - DAY ONE

- Labest

LABEST DAY 1 - Tuesday, May 25th

 

11:00AM - UCLA CHANCELLOR BLOCK WELCOME ADDRESS

11:00 - 11:30AM - KEYNOTE ADDRESS: WHY L.A. 

Los Angeles' attraction as a bioscience ecosystem, its exciting growth, competitive advantages, and its future including hosting the 2028 Summer Olympics, LA28.

Eric Esrailian Eric Esrailian, Chief Vatche & Tamar Manoukian Division of Digestive Diseases, UCLA Health
Gene Sykes Gene Sykes, Co-Chairman of Global Mergers & Acquisitions, Co-Chairman, Global, Technology and Media Telecom Group, Goldman Sachs
Jaime Lee Jaime Lee, President of the Board of Harbor Commissioners for the Port of Los Angeles, Chief Executive Officer, Jamison Realty & Board Member of LA28

 

11:30AM - 11:35AM OPENING REMARKS

David Piaquad David Piacquad, Senior Vice President, Business Development, AMGEN

 

11:35AM - 12:20PM - GROWTH AND RETENTION OF BIOTECH START-UPS IN LOS ANGELES - THE LUNDQUIST INSTITUTE STARTUP AUDITORIUM  Bioscience CEOs will discuss their experiences, decisions, challenges and future opportunities with being located in Los Angeles

Peter Moglia Moderator: Peter Moglia, Co-CEO & Co-Chief Investment Officer, Alexandria Real Estate Equities, Inc.
Bassil Dahiya Bassil Dahiyat, Chief Executive Officer, Xencor
Richard Markus Richard Markus, Chief Executive Officer, Dantari Pharmaceuticals
JJ Kang JJ Kang, Chief Executive Officer, Appia Bio
Hallie Kuhn Hallie Kuhn, Principal, Science & Technology, Alexandria Real Estate Equities, Inc.
 
Dave Licata Dave Licata, President & CEO, 1200 Pharma & TORL Therapeutics

 

12:00PM - 1:15PM MEET LEADERS IN THE BUSINESS OF LIFE SCIENCES - AMGEN AUDITORIUM 

Arie Belldegrun Moderator: Arie Belldegrun, Chief Executive Officer, Bellco Capital
Christi Shaw Christi Shaw - Chief Executive Officer, Kite, A Gilead Company
David Chang David Chang - Chief Executive Office, Allogene Therapeutics
Craig Gordon Craig Gordon - MD, MBA, Former Partner, Capital Group
Daphne Koller Daphne Koller - Chief Executive Officer, insitro
Levi Garraway Levi Garraway - Chief Medical Officer, Genentech

1:00PM - 1:45PM - CIRM STRATEGIC PRIORITIES & OPPORTUNITIES BEYOND 2020 - KITE, A GILEAD COMPANY AUDITORIUM

With the passage of Prop 14, an additional $5.5 billion dollars have been allocated to fund stem cell research. Leaders in the field will discuss strategy and new opportunities in neuropsychiatric and other disorders.

S Thomas Carmichael Moderator: S. Thomas Carmichael, Professor & Frances Stark Endowed Chair, Department of Neurology, Acting Director, Broad Stem Cell Research Center
Maria Millan Maria Millan, President & CEO, California Institute for Regenerative Medicine
Andrew McMahon Andy McMahon, Director of Eli & Edythe Broad CIRM Center for Regenerative Medicine & Stem Cell Research at USC
John Zaia John Zaia, Director for the Center of Gene Therapy, City of Hope
Al Rowlett Al Rowlett, CEO Turning Point Community Programs

1:30 - 2:15 AMGEN R&D/ ACADEMIC STRATEGIES - AMGEN AUDITORIUM 

Industry leaders discuss how to strategically work with academia to develop a pipeline for research, development and talent.

John Mazziotta Moderator: John Mazziotta, Vice Chancellor UCLA Health Sciences, CEO, UCLA Health
Ray Deshaies Ray Deshaies, Head of Global Research, AMGEN
Philip Tagari Philip Tagari, Head of Therapeutic Discovery Research, AMGEN
Tara Arvedson Tara Arvedson, Executive Director, Oncology Research & Global Fastlane Network Lead, AMGEN
Chetan Goudar Chetan Goudar, Vice President, Process Development, AMGEN
Saptarsi Haldar Saptarsi Haldar, Vice President, Cardiometabolic Disorders, AMGEN

2:00PM - 2:30PM : HOW KITE, A GILEAD COMPANY IS BUILDING A GLOBAL CAR-T FRANCHISE OUT OF LOS ANGELES 

Learn how Kite's focus on cell therapy to treat cancer has advanced industry-leading pipeline of chimeric antigen receptor (CAR) and T cell receptor (TCR) product candidates to treat both hematological cancers and solid tumors.

Antonio Bernardo Moderator: Antonio Bernardo - Dean, Anderson School of Business, UCLA
Francesco Marincola Francesco Marincola, Global Head of Cell Therapy Research, Kite, A Gilead Company
Frank Neumann Frank Neumann, Global Head of Clinical Development, Kite, Gilead Company
Matt Hostetler Matt Hostetler, Vice President, Head of Human Resources, Kite, A Gilead Company
Mert Aktar Mert Aktar, Vice President, Head of Corporate Development, Kite, A Gilead Company
  AMGEN AUDITORIUM  KITE, A GILEAD COMPANY AUDITORIUM
2:30PM - 3:00PM  UCLA and Caltech Professor Spotlight Presentations City of Hope Professor Spotlight Presentations
3:00PM - 4:00PM UCLA and Caltech Professor Spotlight Lounge City of Hope Professor Spotlight Lounge

3:00PM - 5:00PM 

Time to explore the LABEST Exhibitor Booths, Pearl Cohen Poster Plaza, Lounge Talks & Jujama Networking